arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Neurocrine Biosciences, Inc.

NBIX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$158.60
▲ +1.9% Today
as of Sep 4, 16:52 ET
Last 30 days -13.91% Jul 29 → Sep 04
$148.05 $158.10 $168.16 $178.22 $188.27 Jul 29 Aug 05 Aug 13 Aug 20 Aug 28 Sep 04
Open
$158.24
High
$159.80
Low
$154.83
Volume
$926,004
Avg Vol
$1M
Mkt Cap
$16.2B
P/E (TTM)
29.15
Beta
—
52w High
$186.12
52w Low
$122.14
Div Yield
—
Shares Out
$102M

Recent Press Releases & News last 60 days · 25 items

Sep 2 · 20:01 PR PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Aug 31 · 16:33 Zacks
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
Aug 28 · 02:18 Simply Wall St.
Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$122
$186
57% of range
Avg surprise (last 3)
-21.0%
Avg reaction (last 2)
+0.4%
100% positive
Latest IV / EM
28%
EM ±4.4% · $160 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.79$-0.08$0.62$1.33$2.04 Actual $-0.79Actual $0.95Actual $0.82Actual $0.42Actual $0.63Actual $1.24Actual $0.08Est $0.43Actual $1.06Est $0.98Actual $2.04Actual $1.41Est $1.28Actual $1.39 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$0$252M$503M$755M$1.0B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $1.39 — — — — financials
Tue May 5, 2026Mar/2026 $1.41 $1.28 +10.2% +1,662% +0.7% earnings
Tue Sep 30, 2025Sep 2025 $2.04 — — — — financials
Wed Jul 30, 2025Jun/2025 $1.06 $0.98 +8.2% — — earnings
Mon May 5, 2025Mar/2025 $0.08 $0.43 -81.4% — +0.1% earnings
Mon Sep 30, 2024Sep 2024 $1.24 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.63 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.42 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.82 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.95 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.79 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$959M$814M—$795M$688M$573M—$622M
Cost of revenue—$14M—$14M$11M$9M—$8M
Gross profit————————
Operating income$152M$193M—$239M$146M$24M—$184M
Net income$144M$198M—$210M$108M$8M—$130M
EPS (diluted)$1.39$1.91—$2.04$1.06$0.08—$1.24

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$332M$266M$713M$340M$264M$194M$233M$349M
Inventory$104M$64M$69M$69M$57M$59M$57M$46M
Total current assets$1.64B$2.44B$2.52B$2.16B$1.75B$1.64B$1.72B$1.88B
Total assets$5.36B$4.91B$4.63B$4.27B$3.89B$3.69B$3.72B$3.54B
Long-term debt————————
Total liabilities$1.67B$1.50B$1.38B$1.26B$1.20B$1.15B$1.13B$816M
Total equity$3.69B$3.41B$3.25B$3.00B$2.69B$2.54B$2.59B$2.72B

Implied volatility — last 90 days

25%46%67%88%109% Jun 07 — IV 44% · EM ±6.1%Jun 08 — IV 46% · EM ±6.0%Jun 09 — IV 46% · EM ±5.7%Jun 10 — IV 52% · EM ±6.2%Jun 11 — IV 48% · EM ±5.3%Jun 12 — IV 48% · EM ±4.9%Jun 15 — IV 65% · EM ±4.7%Jun 16 — IV 60% · EM ±3.5%Jun 17 — IV 109% · EM ±4.6%Jun 19 — IV 32% · EM ±7.0%Jun 22 — IV 33% · EM ±6.8%Jun 23 — IV 29% · EM ±5.9%Jun 24 — IV 31% · EM ±6.3%Jun 25 — IV 31% · EM ±6.1%Jun 26 — IV 28% · EM ±5.3%Jun 29 — IV 29% · EM ±5.1%Jun 30 — IV 27% · EM ±4.7%Jul 01 — IV 27% · EM ±4.4%Jul 02 — IV 25% · EM ±4.1%Jul 03 — IV 26% · EM ±4.1%Jul 06 — IV 28% · EM ±3.9%Jul 07 — IV 33% · EM ±4.3%Jul 08 — IV 28% · EM ±3.6%Jul 09 — IV 28% · EM ±3.4%Jul 10 — IV 30% · EM ±3.3%Jul 13 — IV 30% · EM ±2.5%Jul 14 — IV 47% · EM ±3.4%Jul 15 — IV 40% · EM ±2.4%Jul 16 — IV 77% · EM ±3.2%Jul 20 — IV 43% · EM ±10.1%Jul 21 — IV 43% · EM ±10.0%Jul 22 — IV 43% · EM ±9.8%Jul 23 — IV 44% · EM ±9.9%Jul 24 — IV 45% · EM ±9.9%Jul 27 — IV 45% · EM ±9.5%Jul 28 — IV 47% · EM ±9.5%Jul 29 — IV 46% · EM ±9.2%Jul 30 — IV 48% · EM ±9.3%Jul 31 — IV 31% · EM ±6.0%Aug 03 — IV 29% · EM ±5.1%Aug 04 — IV 30% · EM ±5.1%Aug 05 — IV 29% · EM ±4.9%Aug 06 — IV 32% · EM ±5.2%Aug 07 — IV 28% · EM ±4.3%Aug 10 — IV 26% · EM ±3.6%Aug 11 — IV 30% · EM ±3.9%Aug 12 — IV 32% · EM ±4.0%Aug 13 — IV 32% · EM ±3.8%Aug 14 — IV 29% · EM ±3.2%Aug 17 — IV 37% · EM ±3.1%Aug 18 — IV 28% · EM ±2.0%Aug 19 — IV 32% · EM ±1.9%Aug 20 — IV 92% · EM ±3.8%Aug 24 — IV 31% · EM ±6.5%Aug 25 — IV 29% · EM ±5.9%Aug 26 — IV 27% · EM ±5.3%Aug 27 — IV 27% · EM ±5.3%Aug 28 — IV 27% · EM ±5.3%Aug 31 — IV 28% · EM ±4.9%Sep 01 — IV 28% · EM ±4.8%Sep 02 — IV 28% · EM ±4.8%Sep 03 — IV 26% · EM ±4.2%Sep 04 — IV 28% · EM ±4.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in